↓ Skip to main content

Dove Medical Press

Continuous delivery of propranolol from liposomes-in-microspheres significantly inhibits infantile hemangioma growth

Overview of attention for article published in International Journal of Nanomedicine, September 2017
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (71st percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

blogs
1 blog
facebook
2 Facebook pages

Citations

dimensions_citation
24 Dimensions

Readers on

mendeley
24 Mendeley
Title
Continuous delivery of propranolol from liposomes-in-microspheres significantly inhibits infantile hemangioma growth
Published in
International Journal of Nanomedicine, September 2017
DOI 10.2147/ijn.s137634
Pubmed ID
Authors

Xiaonan Guo, Xiaoshuang Zhu, Dakan Liu, Yubin Gong, Jing Sun, Changxian Dong

Abstract

To reduce the adverse effects and high frequency of administration of propranolol to treat infantile hemangioma, we first utilized propranolol-loaded liposomes-in-microsphere (PLIM) as a novel topical release system to realize sustained release of propranolol. PLIM was developed from encapsulating propranolol-loaded liposomes (PLs) in microspheres made of poly(lactic-co-glycolic acid)-b-poly(ethylene glycol)-b-poly(lactic-co-glycolic acid) copolymers (PLGA-PEG-PLGA). The release profile of propranolol from PLIM was evaluated, and its biological activity was investigated in vitro using proliferation assays on hemangioma stem cells (HemSCs). Tumor inhibition was studied in nude mice bearing human subcutaneous infantile hemangioma. The microspheres were of desired particle size (~77.8 μm) and drug encapsulation efficiency (~23.9%) and achieved sustained drug release for 40 days. PLIM exerted efficient inhibition of the proliferation of HemSCs and significantly reduced the expression of two angiogenesis factors (vascular endothelial growth factor-A [VEGF-A] and basic fibroblast growth factor [bFGF]) in HemSCs. Notably, the therapeutic effect of PLIM in hemangioma was superior to that of propranolol and PL in vivo, as reflected by significantly reduced hemangioma volume, weight, and microvessel density. The mean hemangioma weight of the PLIM-treated group was significantly lower than that of other groups (saline =0.28 g, propranolol =0.21 g, PL =0.13 g, PLIM =0.03 g; PLIM vs saline: P<0.001, PLIM vs propranolol: P<0.001, PLIM vs PL: P<0.001). The mean microvessel density of the PLIM-treated group was significantly lower than that of other groups (saline =40 vessels/mm(2), propranolol =31 vessels/mm(2), PL =25 vessels/mm(2), PLIM =11 vessels/mm(2); PLIM vs saline: P<0.001, PLIM vs propranolol: P<0.01, PLIM vs PL: P<0.05). Our findings show that PLIM is a very promising approach to locally and efficiently deliver propranolol to the hemangioma site leading to a significant inhibition of infantile hemangioma.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 24 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 4 17%
Other 2 8%
Professor > Associate Professor 2 8%
Student > Ph. D. Student 2 8%
Unspecified 1 4%
Other 2 8%
Unknown 11 46%
Readers by discipline Count As %
Medicine and Dentistry 5 21%
Pharmacology, Toxicology and Pharmaceutical Science 3 13%
Unspecified 1 4%
Agricultural and Biological Sciences 1 4%
Biochemistry, Genetics and Molecular Biology 1 4%
Other 2 8%
Unknown 11 46%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 November 2017.
All research outputs
#6,354,972
of 25,382,440 outputs
Outputs from International Journal of Nanomedicine
#639
of 4,122 outputs
Outputs of similar age
#91,104
of 324,453 outputs
Outputs of similar age from International Journal of Nanomedicine
#11
of 102 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 4,122 research outputs from this source. They receive a mean Attention Score of 4.7. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,453 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 102 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.